Cocrystal Pharma Inc. Common Stock (COCP)

FairStock Score: 52/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

In the Graham-Buffett tradition, I want a business with durable earnings, honest accounting, and a margin of safety. Cocrystal does not yet offer that. It is a 10-employee antiviral discovery company. In fiscal Q2 2026 (quarter ended 2026-06-30), revenue was $105,000 and net loss was $3.2 million, or $0.23 per diluted share. Fiscal Q1 2026 (quarter ended 2026-03-31) showed $225,000 revenue and a $2.3 million loss. For FY2025 (period ended 2025-12-31), net loss was $8.8 million, or $0.78 per share; FY2024 lost $17.5 million; FY2023 lost $18.0 million. The FairStock Lynch category is none because the company lost money in each of the last four years. Financial strength is poor: Piotroski 1/9, Altman Z-score -103.32, debt-to-equity 1.28, and trailing free cash flow of -$8.0 million, a -38.3% FCF yield against the $20.8 million market cap. The price is $1.08 as of 2026-10-13. P/B is 13.50 and P/E is -1.44, so there is no earnings-based value support. A pipeline in influenza, norovirus, coronaviruses, and hepatitis C could become valuable, but that is speculative. Until it produces recurring revenue or a partnership that funds development, I see no moat, no demonstrated earning power, and no margin of safety. This is a lottery ticket on clinical success, not a Graham bargain.

In plain English: Cocrystal Pharma is a small company working on antiviral medicines for serious viral diseases. It is not yet a strong business: it has lost money for years and brings in very little revenue. At $1.08 a share, with a market value of about $20.8 million, the price looks expensive compared with its current sales and losses.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer